- Report
- November 2023
- 104 Pages
Global
From €3500EUR$4,243USD£3,171GBP
- Report
- May 2023
- 98 Pages
Global
From €3500EUR$4,243USD£3,171GBP
- Report
- August 2024
- 86 Pages
Global
From €3500EUR$4,243USD£3,171GBP
- Report
- September 2023
- 98 Pages
Global
From €3500EUR$4,243USD£3,171GBP
- Report
- November 2025
- 132 Pages
Global
From €840EUR$950USD£735GBP
- Report
- November 2025
- 132 Pages
Global
From €840EUR$950USD£735GBP
- Report
- November 2025
- 132 Pages
Global
From €840EUR$950USD£735GBP
- Report
- November 2025
- 132 Pages
Global
From €840EUR$950USD£735GBP
- Report
- April 2024
- 132 Pages
Global
From €840EUR$950USD£735GBP

The Protein Drugs market is a subset of the larger Drug Discovery industry. It focuses on the development of drugs that are based on proteins, such as monoclonal antibodies, cytokines, and growth factors. These drugs are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. Protein drugs are typically developed through recombinant DNA technology, which involves the manipulation of genetic material to create a desired protein.
The Protein Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are engaged in research and development of new protein drugs, as well as the marketing and distribution of existing drugs. Show Less Read more